S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
NASDAQ:AKRX

Akorn (AKRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.09
$0.32
52-Week Range
N/A
Volume
1.19 million shs
Average Volume
9.60 million shs
Market Capitalization
$3.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKRX stock logo

About Akorn Stock (NASDAQ:AKRX)

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

AKRX Stock News Headlines

Akorn Reaches New 52-Week High (AKRX)
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
Delaware Powerhouse: Paul Weiss - Law360
See More Headlines
Receive AKRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2020
Today
4/18/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AKRX
CUSIP
00972810
CIK
3116
Fax
N/A
Employees
2,227
Year Founded
N/A

Profitability

Net Income
$-226,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$682.43 million
Book Value
$1.86 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.60 million
Optionable
Optionable
Beta
0.95
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Duane A. Portwood (Age 53)
    Exec. VP & CFO
  • Mr. Joseph Bonaccorsi (Age 54)
    Exec. VP, Gen. Counsel & Sec.
  • Mr. Jonathan Kafer (Age 56)
    Exec. VP & Chief Commercial Officer
  • Dr. Bruce Kutinsky (Age 53)
    Consultant
  • Mr. Douglas S. Boothe (Age 55)
    Pres, CEO & Direcor

AKRX Stock Analysis - Frequently Asked Questions

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) posted its quarterly earnings data on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.45. The business earned $204.69 million during the quarter, compared to the consensus estimate of $168.90 million. Akorn had a negative net margin of 55.64% and a positive trailing twelve-month return on equity of 8.53%.

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Block (SQ).

This page (NASDAQ:AKRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners